3 recruiting, 2 completed. 5 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Recruiting 3, Completed 2 |
| Phase 2 | 1 | Recruiting 1 |
Follow this drug Literature Review of D2C7-(scdsFv)-PE38KDEL trials Research Report on D2C7-(scdsFv)-PE38KDEL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| D2C7-IT + 2141-V11 Combination Post-resection in rGBM D2C7-IT, 2141 V11 - Recurrent Glioblastoma IDH Wildtype | Phase 1 | Recruiting | Darell Bigner | 46 | 2025-03-17 | 2026-10-21 |
| D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients D2C7-IT, 2141-V11 - Newly Diagnosed MGMT Unmethylated Glioblastoma | Phase 1 / Phase 2 | Recruiting | Darell Bigner | 50 | 2023-09-06 | 2026-10-16 |
| Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma D2C7-IT, 2141-V11 - Glioma, Malignant | Phase 1 | Recruiting | Darell Bigner | 90 | 2021-07-09 | 2026-06-04 |
| D2C7-IT With Atezolizumab for Recurrent Gliomas D2C7-IT (6920 ng/mL via convection-enhanced delivery), Atezolizumab (1200 mg every three weeks), D2C7-IT (4613.2 ng/mL via convection-enhanced delivery) - Malignant Glioma | Phase 1 | Completed | Darell Bigner | 14 | 2020-02-25 | 2026-10-14 |
| D2C7 for Adult Patients With Recurrent Malignant Glioma D2C7-IT - Malignant Glioma, Brain Tumor, Recurrent | Phase 1 | Completed | Darell Bigner | 81 | 2015-05-05 | 2026-06-26 |
Glioblastoma (4) · Glioma (3) · Brain Neoplasms (1)
Darell Bigner (5)
United States (5)
Annick Desjardins, MD (2) · Annick Desjardins, MD, FRCPC (1) · Annick Desjardins, MD,FRCPC (1) · Daniel Landi, MD (1)